CC BY 4.0 · VCOT Open 2024; 07(S 01): A1-A12
DOI: 10.1055/s-0044-1786230
Resident Session Abstracts

Evaluation of the Effect of Cannabidiol Administration with and without Nonsteroidal Anti-inflammatory Drugs in Dogs with Mobility Disorders: A Prospective, Double-blind, Crossover, Placebo-controlled Study

B. N. Talsma
1   Department of Clinical Sciences, Colorado State University College of Veterinary and Biomedical Sciences, Fort Collins, Colorado, United States
,
F. M. Duerr
1   Department of Clinical Sciences, Colorado State University College of Veterinary and Biomedical Sciences, Fort Collins, Colorado, United States
,
S. McGrath
1   Department of Clinical Sciences, Colorado State University College of Veterinary and Biomedical Sciences, Fort Collins, Colorado, United States
,
T. Zhou
2   Department of Statistics, Colorado State University, Fort Collins, Colorado, United States
,
C. B. Webb
1   Department of Clinical Sciences, Colorado State University College of Veterinary and Biomedical Sciences, Fort Collins, Colorado, United States
,
L. H. Elam
1   Department of Clinical Sciences, Colorado State University College of Veterinary and Biomedical Sciences, Fort Collins, Colorado, United States
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction: Given the growing interest for cannabidiol (CBD) in the management of pain and other conditions, more information is needed on the safety and efficacy of this supplement, particularly regarding its co-administration with common pharmaceuticals such as non-steroidal anti-inflammatory drugs (NSAIDs). The objectives of this study were to objectively assess the effect of CBD in dogs with mobility impairments and to evaluate the clinical tolerance of CBD used together with NSAIDs.

    Materials and Methods: Forty-two client-owned dogs with diagnosed mobility impairments were enrolled in this prospective, double-blind, crossover, placebo-controlled study. Both dogs receiving regular NSAID therapy and not receiving NSAIDs were enrolled. Baseline data was collected for 10 days before random allocation to first receive placebo or CBD oil for 45 days with a 30-day washout period before receiving the opposite treatment. Outcome measures included objective gait analysis, accelerometry, veterinary assessment, and clinical metrology instruments.

    Results: Dogs receiving CBD showed evidence of improved outcomes on both subjective and objective outcome measures. Fifteen dogs (36%) experienced liver enzyme elevations (73% ALP, 33% ALT) while receiving CBD. Five of 15 underwent further hepatic work-up with no clinically apparent liver damage identified. There was no evidence of an association between liver enzyme elevations and NSAID use.

    Discussion/Conclusion: These results suggest a potential therapeutic benefit in the administration of CBD for the management of mobility impairments as well as its tolerance when co-administered with NSAIDs in dogs. Further research is needed to better understand these effects in a larger population of dogs and long-term.

    Acknowledgment:

    Funding, CBD, and placebo products for this study were provided by cbdMD.


    #

    Publication History

    Article published online:
    09 April 2024

    © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany